Medications

What Is Zepbound? Everything You Need to Know About Tirzepatide

GLP-1 Companion · 7 min read

Zepbound (tirzepatide) made headlines in November 2023 when the FDA approved it specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. While the same molecule already existed as Mounjaro for type 2 diabetes, the Zepbound approval gave patients and insurers a clear, dedicated weight-loss indication.

What Is Zepbound?

Zepbound is the brand name for tirzepatide when prescribed for weight management. It is manufactured by Eli Lilly and delivered as a once-weekly subcutaneous injection. Like Mounjaro, it acts as a dual GLP-1 and GIP receptor agonist, targeting two key incretin hormones involved in appetite regulation, insulin secretion, and energy metabolism.

Who Is Eligible for Zepbound?

Zepbound is approved for adults with a body mass index (BMI) of 30 or greater (obesity), or a BMI of 27 or greater (overweight) who also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. It is intended to be used alongside a reduced-calorie diet and increased physical activity.

How Zepbound Works

Tirzepatide mimics two naturally occurring incretin hormones. GLP-1 slows stomach emptying, reduces appetite, and improves insulin sensitivity. GIP complements these effects by further enhancing insulin response and potentially influencing fat metabolism. Together, these dual signals create a powerful feedback loop that reduces hunger, increases satiety, and helps the body manage blood sugar more efficiently.

Dosing Schedule

Zepbound follows the same tirzepatide dosing escalation as Mounjaro. The gradual increase helps minimize gastrointestinal side effects.

1. Weeks 1–4: 2.5 mg once weekly (initiation dose)
2. Weeks 5–8: 5 mg once weekly
3. Weeks 9–12: 7.5 mg once weekly (optional escalation)
4. Weeks 13–16: 10 mg once weekly
5. Week 17 onward: 12.5 mg or 15 mg once weekly (maximum dose)

Your provider may slow down the escalation if side effects are difficult to manage. There is no requirement to reach the maximum dose—many patients achieve meaningful results at 10 mg or even 7.5 mg.

Zepbound vs. Mounjaro: Key Differences

Since both medications contain tirzepatide, the pharmacology is identical. The differences are regulatory and commercial:

• Indication: Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management.
• Insurance coverage: Health plans may cover one brand but not the other depending on your diagnosis.
• Pricing: Both have similar list prices, but copay programs and coverage vary.
• Prescribing: A provider may choose one brand over the other based on your primary health concern and insurance formulary.

Clinical Trial Results

Zepbound's approval was based on the SURMOUNT clinical trial program, which studied tirzepatide in adults with obesity or overweight without diabetes.

• SURMOUNT-1: Participants on the 15 mg dose lost an average of 22.5% of body weight (approximately 52 lbs) over 72 weeks.
• SURMOUNT-2: In adults with type 2 diabetes and obesity, the 15 mg dose produced an average weight loss of 14.7%.
• SURMOUNT-3: When combined with intensive lifestyle intervention, participants lost up to 26.6% of body weight.
• SURMOUNT-4: Demonstrated that continued treatment maintained weight loss, while those who switched to placebo regained a significant portion of lost weight.

In SURMOUNT-1, more than one in three participants on the highest dose lost over 25% of their body weight—results that rival bariatric surgery outcomes.

Cost and Insurance Coverage

Zepbound's list price is approximately $1,060 per month without insurance. However, actual out-of-pocket costs vary widely depending on your health plan, pharmacy benefits, and eligibility for savings programs.

• Eli Lilly offers a savings card that may reduce the cost to as low as $25 per month for eligible commercially insured patients.
• Medicare Part D and many Medicaid plans historically have not covered weight-loss medications, though this is evolving.
• Some employers are adding GLP-1 weight-loss coverage to their benefits packages.
• Cash-pay options through telehealth platforms or specialty pharmacies may offer lower pricing.

Common Side Effects

• Nausea (most frequent, especially during dose escalation)
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Indigestion
• Injection site reactions
• Hair thinning (reported by some patients during rapid weight loss)

Most gastrointestinal side effects are mild to moderate and tend to decrease as your body adjusts. Eating smaller meals, avoiding fatty foods, and staying well-hydrated can help manage symptoms.

What Results Can You Expect?

Individual results vary, but clinical data provides a general benchmark. Most patients begin noticing appetite changes within the first 2–4 weeks. Measurable weight loss typically becomes apparent by weeks 8–12. Peak weight loss in clinical trials was observed around weeks 60–72, with benefits sustained as long as treatment continued. Combining Zepbound with dietary changes and regular physical activity tends to produce the best and most lasting outcomes.

The Bottom Line

Zepbound is one of the most effective weight-loss medications available today, offering the same proven tirzepatide molecule as Mounjaro but with a dedicated obesity indication. If you have a BMI of 30 or higher—or 27 or higher with a weight-related condition—talk to your healthcare provider about whether Zepbound could be part of your weight management plan.

Sources

• Zepbound (tirzepatide) Prescribing Information. Eli Lilly.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.